Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With... Micro-AbstractWe assessed the relationship between different intermediate criteria and overall survival (OS) in metastatic colorectal cancer patients who received first-line chemotherapy with bevacizumab. Duration of disease control and time to failure of strategy were strongly correlated with OS, which makes them relevant as intermediate criteria in future clinical trials. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Colorectal Cancer Elsevier

Clinical Relevance of Alternative Endpoints in Colorectal Cancer First-Line Therapy With Bevacizumab: A Retrospective Study

Loading next page...
 
/lp/elsevier/clinical-relevance-of-alternative-endpoints-in-colorectal-cancer-first-LTt0KE6GFQ
Publisher
Elsevier
Copyright
Copyright © 2017 Elsevier Inc.
ISSN
1533-0028
eISSN
1936-0674
D.O.I.
10.1016/j.clcc.2017.10.001
Publisher site
See Article on Publisher Site

Abstract

Micro-AbstractWe assessed the relationship between different intermediate criteria and overall survival (OS) in metastatic colorectal cancer patients who received first-line chemotherapy with bevacizumab. Duration of disease control and time to failure of strategy were strongly correlated with OS, which makes them relevant as intermediate criteria in future clinical trials.

Journal

Clinical Colorectal CancerElsevier

Published: Mar 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off